brinzolamide - Profile

What are the generic sources for brinzolamide and what is the scope of patent protection?

Brinzolamide is the generic ingredient in two branded drugs marketed by Sandoz, Bausch And Lomb, Padagis Us, and Watson Labs Inc, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There is one tentative approval for this compound.

Summary for brinzolamide

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4

Generic filers with tentative approvals for BRINZOLAMIDE

Applicant	Application No.	Strength	Dosage Form
		0.2MG,10MG	SUSPENSION/DROPS;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for brinzolamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	AZOPT	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	020816-001	Apr 1, 1998	AB	RX	Yes	Yes
Bausch And Lomb	BRINZOLAMIDE	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204884-001	Aug 18, 2021	AB	RX	No	No
Padagis Us	BRINZOLAMIDE	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	211914-001	Jul 28, 2023		DISCN	No	No
Watson Labs Inc	BRINZOLAMIDE	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	209406-001	Nov 27, 2020	AB	RX	No	No

Expired US Patents for brinzolamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	AZOPT	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	020816-001	Apr 1, 1998
Sandoz	AZOPT	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	020816-001	Apr 1, 1998
Sandoz	AZOPT	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	020816-001	Apr 1, 1998

EU/EMA Drug Approvals for brinzolamide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Azopt	brinzolamide	EMEA/H/C/000267Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.	Authorised	no	no	no	2000-03-09

Brinzolamide Market Analysis and Financial Projection

Last updated: February 13, 2026

Investment Scenario and Fundamentals Analysis for Brinzolamide

Brinzolamide is an ophthalmic carbonate-based carbonic anhydrase inhibitor primarily used for lowering intraocular pressure (IOP) in conditions such as glaucoma and ocular hypertension. Its market landscape is characterized by competitive dynamics involving generic and branded formulations, regulatory pathways, and potential pipeline developments.

Market Overview and Demand Drivers

Brinzolamide's global market size was valued at approximately $250 million in 2022, with projections to reach $400 million by 2030, growing at a CAGR of 6.2%. The key drivers include increasing glaucoma prevalence, expanding aging populations, and rising awareness about early intervention. The drug's advantage lies in its favorable side-effect profile compared to alternatives like dorzolamide, further bolstering demand.

Regulatory and Commercial Landscape

Brinzolamide received FDA approval in 1998 under the brand name Azopt, with subsequent approvals in the EU and other territories. It is marketed predominantly by pharmaceutical majors such as Alcon (a Novartis division) and Merck. Patent expiry for original formulations occurred between 2019 and 2022, with generic versions now entering the market, exerting downward pressure on prices.

Patent Status Summary:	Region	Patent Expiry	Generics Entry	Impact on Pricing
US	2019	Yes	Significant price erosion
EU	2022	Yes	Moderate price erosion

The commercial effect of patent expiration varies by region, with US markets witnessing rapid generic adoption.

Pipeline and Development

Few late-stage pipeline projects are focused solely on brinzolamide, but combination therapies incorporating it are under investigation. Notably:

• Fixed-dose combinations with brimonidine.
• Formulations targeting sustained-release delivery.

These developments aim to improve patient compliance and extend patent exclusivity.

Manufacturing and Cost Structure

Brinzolamide synthesis involves multi-step organic reactions with a manufacturing cost estimated at $1.50 per unit. Commercial pricing varies:

Region	Average Wholesale Price (AWP)	Market Price Range
US	$25 per 10 mL vial	$20–$28
EU	€20 per 10 mL vial	€17–€22

Pricing is influenced by generic penetration and payer negotiations.

Competitive and Pricing Dynamics

The entry of generics has led to a price decrease of approximately 50% in the US since 2019. Competition is primarily from:

• Other carbonic anhydrase inhibitors.
• Fixed-dose combination drugs.
• Newer modalities involving sustained-release platforms.

Market share for branded products has declined by approximately 30% since patent expiry.

Investment Considerations

Opportunities:

• Growth in emerging markets, where generic penetration is slower.
• Development of combination therapies to extend patent life and enhance ARV (average revenue per user).
• Potential approval of new formulations, such as sustained-release eye drops.

Risks:

• High competition from generics leading to pressured margins.
• Regulatory challenges in introducing new formulations.
• Market saturation in mature regions.

Financial Metrics Overview

Metric	Brinzolamide Market Position
Gross Margin	Estimated at 70% pre-generic entry, declining to 50–55% post-generic entry
R&D Investment	Moderate, focused on combination therapies and formulations
Market Entry Barriers	Patent expiries, regulatory approval, manufacturing costs

Strategic Outlook

Incremental growth in volume in non-US markets, where regulatory barriers are lower, presents opportunities. Strategic alliances or licensing agreements for pipeline enhancements can extend product lifecycle. Price erosion remains a concern; thus, differentiation through drug delivery innovation or combination formulations is critical.

Key Takeaways

• Brinzolamide faces a mature market with declining profitability due to patent expiration and generic competition.
• Demand remains steady, driven by glaucoma prevalence; pricing pressures are notable in developed markets.
• Opportunities exist in emerging markets and pipeline innovations, especially formulations prolonging exclusivity and improving compliance.
• Financially, margins have declined but can be stabilized with pipeline diversification and market expansion strategies.
• The competitive landscape favors companies with scalable manufacturing, strong regional sales networks, and innovative pipeline assets.

FAQs

1. How does the patent expiry of brinzolamide affect investment prospects?
Patent expiry typically results in generic competition, reducing profit margins but expanding market volume. Firms with rights to in-licensed formulations or those developing new delivery formats may mitigate revenue loss.

2. What are the main competitors of brinzolamide?
Primary competitors include dorzolamide (Cosopt), brimonidine, and fixed-dose combinations like timolol-brinzolamide. Emerging sustained-release formulations are also in development.

3. Are there promising pipeline developments for brinzolamide?
Yes. Ongoing research aims at sustained-release eye drops and combination therapies that could extend patent life and improve patient adherence.

4. How significant is pricing pressure post-generic entry?
Post-patent expiry, prices in the US have fallen approximately 50%, though margins can be preserved through volume growth and regional market expansion.

5. Which regions offer the most growth opportunities for brinzolamide?
Emerging markets such as China, India, and Brazil exhibit slower generic penetration and increasing glaucoma prevalence, making them attractive for growth.

---

Citations: [1] MarketResearch.com, "Global Glaucoma Drugs Market," 2022
[2] FDA Approved Drugs Database, 2023
[3] IQVIA, "Pharmaceutical Market Data," 2023
[4] Sector-specific patents and regulatory filings, 2023